Key result
Alagebrium increased endothelial flow-mediated dilation from 4.6% to 7.1% (P<0.05) and reduced carotid augmentation index by 37% (P=0.007) in adults with isolated systolic hypertension.
Why the study?
Does oral alagebrium improve endothelial flow-mediated dilation and arterial stiffness in adults with isolated systolic hypertension?
Population
13 adults with isolated systolic hypertension on stable antihypertensive therapy
Comparison
Oral alagebrium 210 mg twice a day for 8 weeks vs Placebo for 2 weeks prior to alagebrium therapy
Design
Other, Subjects and data analyses were blinded to treatment
Follow-up
8 weeks
Authors
Loading...
Alagebrium may enhance vascular function in isolated systolic hypertension; leaves open effects on clinical outcomes.
Does oral alagebrium improve endothelial flow-mediated dilation and arterial stiffness in adults with isolated systolic hypertension?
Absolute Event Rate: 7.1% vs 4.6%
p-value: p=< 0.05
Alagebrium, an advanced glycation endproduct crosslink breaker, improves endothelial function and reduces central arterial stiffness in older adults with isolated systolic hypertension.
Zieman et al. (2007) studied Isolated systolic hypertension (n=13). Alagebrium (ALT-711) vs. Placebo was evaluated on Endothelial flow-mediated dilation (FMD) (p=< 0.05). Alagebrium increased endothelial flow-mediated dilation from 4.6% to 7.1% (P<0.05) and reduced carotid augmentation index by 37% (P=0.007) in adults with isolated systolic hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: